Literature DB >> 8184534

Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975.

R F Massung1, L I Liu, J Qi, J C Knight, T E Yuran, A R Kerlavage, J M Parsons, J C Venter, J J Esposito.   

Abstract

We analyzed the 186,102 base pairs (bp) that constitute the entire DNA genome of a highly virulent variola virus isolated from Bangladesh in 1975. The linear, double-stranded molecule has relatively small (725 bp) inverted terminal repeat (ITR) sequences containing three 69-bp direct repeat elements, a 54-bp partial repeat element, and a 105-base telomeric end-loop that can be maximally base-paired to contain 17 mismatches. Proximal to the right-end ITR sequences are another seven 69-bp elements and a 53- and a 27-bp partial element. Sequence analysis showed 187 closely spaced open reading frames specifying putative major proteins containing > or = 65 amino acids. Most of the virus proteins correspond to proteins in current databases, including 150 proteins that have > 90% identity to major gene products encoded by vaccinia virus, the smallpox vaccine. Variola virus has a group of proteins that are truncated compared with vaccinia virus counterparts and a smaller group of proteins that are elongated. The terminal regions encode several novel proteins and variants of other poxvirus proteins that potentially augment variola virus transmissibility and virulence for its only natural host, humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8184534     DOI: 10.1006/viro.1994.1288

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  82 in total

1.  Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.

Authors:  S A Smith; N P Mullin; J Parkinson; S N Shchelkunov; A V Totmenin; V N Loparev; R Srisatjaluk; D N Reynolds; K L Keeling; D E Justus; P N Barlow; G J Kotwal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses.

Authors:  M Saraiva; A Alcami
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Detection of smallpox virus DNA by LightCycler PCR.

Authors:  Mark J Espy; Franklin R Cockerill III; Richard F Meyer; Michael D Bowen; Gregory A Poland; Ted L Hadfield; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome.

Authors:  Chris Upton; Stephanie Slack; Arwen L Hunter; Angelika Ehlers; Rachel L Roper
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Detection of orthopoxvirus DNA by real-time PCR and identification of variola virus DNA by melting analysis.

Authors:  Andreas Nitsche; Heinz Ellerbrok; Georg Pauli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

7.  In celebration of the 200th anniversary of Edward Jenner's Inquiry into the causes and effects of the variolae vaccinae.

Authors:  R C Brunham; K M Coombs
Journal:  Can J Infect Dis       Date:  1998-09

8.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

9.  Strategy for identifying the gene encoding the DNA polymerase of molluscum contagiosum virus type 1.

Authors:  K C Sonntag; G Darai
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

10.  Two types of deletions in orthopoxvirus genomes.

Authors:  S N Shchelkunov; A V Totmenin
Journal:  Virus Genes       Date:  1995-02       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.